Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Zealand Pharma Ord Shs ZLDPF

Healthcare Biotechnology
Zealand Pharma A/S is a Denmark-based biotechnology company. The Company is focused on the discovery, design and development of peptide-based medicines for metabolic and gastrointestinal diseases and other rare disease areas with unmet medical needs. The Company's peptide-based product candidates includes clinical development, registration and, potentially, commercialization. Its pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome, or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for better diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The Company operates in Denmark and the USA and has a portfolio of medicines and product candidates, including collaborations with Boehringer Ingelheim.


PINL:ZLDPF - Post by User

Zealand Pharma Ord Shs
<< Previous
 Bullboard Posts
User Avatar Image
(119)
•••
Post by whytestockson Jun 25, 2024 3:00pm
17 Views
Post# 36105566

Zealand Pharma announces upsizing of previously announced eq

Zealand Pharma announces upsizing of previously announced eq
BREAKING NEWS: $ZLDPF Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billionCompany announcement &#x2013; No. 34 / 2024 Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR INTO T...ZLDPF - Zealand Pharma announces upsizing of previously announced equity offering from approximately USD 900 million / DKK 6.257 billion to USD 1 billion / DKK 7 billion

<< Previous
 Bullboard Posts
Dealroom for high-potential pre-IPO opportunities